Thyroid Dysfunction in 281 Patients with Metastatic Melanoma or Renal Carcinoma Treated with Interleukin-2 Alone

Journal of Immunotherapy

Volumn 18, Issue 4, 1995, Pages 272-278

  Krouse, Robert S ^a   Royal, Richard E ^a   Heywood, Glenroy ^a   Weintraub, Bruce D ^b   White, Donald E ^a   Steinberg, Seth M ^a   Rosenberg, Steven A ^a   Schwartzentruber, Douglas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Hyperthyroidism; Hypothyroidism; IL 2; Melanoma; Renal carcinoma

Indexed keywords

INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; THYROID DISEASE; THYROID FUNCTION TEST;

ADOLESCENT; ADULT; AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNOTHERAPY, ACTIVE; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; PROSPECTIVE STUDIES; THYROID GLAND;

EID: 0029550054     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199511000-00008     Document Type: Article

References (23)

1. Rosenberg SA, Yang JC, Topalian SL, et al. The treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994;271:907-13.
2. Whittington R, Faulds D. Interleukin-2: a review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 1993;46:446-514.
3. Schwartzentruber DJ. Biologic therapy with interleukin-2: clinical applications. Principles of administration and management of side effects. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Biologic therapy of cancer, 2nd ed. Philadelphia: JB Lippincott, 1995:235-49.
4. Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 1988;318:1557-63.
5. Weijl NI, Van Der Harst D, Brand A, et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol 1993;11:1376-83.
6. Kruit WHJ, Bolhuis RLH, Goey SH, et al. Interleukin-2- induced thyroid dysfunction is correlated with treatment duration but not with tumor response. J Clin Oncol 1993;11:921-4.
7. Schwartzentruber DJ, White DE, Zweig MH, Wientraub BD, Rosenberg SA. Thyroid dysfunction associated with immunotherapy for patients with cancer. Cancer 1991;68:2384-90.
8. Scalzo S, Gengaro A, Boccoli G, et al. Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma. Eur J Cancer 1990;26:1152-6.
9. Reid I, Sharpe I, McDevitt J, Maxwell W, Emmons R, Tanner W, Monson JRT. Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2α. Br J Cancer 1991;64:915-8.
10. Jacobs EL, Clare-Salzler MJ, Chopra IJ, Figlin RA. Thyroid function abnormalities associated with the chronic administration of recombinant interleukin-2 and recombinant interferon-alpha. J Immunother 1991;10:448-55.
11. Pichert G, Jost LM, Zöbeli L, Odermatt B, Pedio G, Stahel RA. Thyroiditis after treatment with interleukin-2 and interferon α-2a. Br J Cancer 1990;62:100-4.
12. Vialettes B, Guillerand MA, Viens P, et al. Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignancies. Acta Endocrinol 1993;129:31-8.
13. Vassilopoulou-Sellin R, Sella A, Dexeus FH, Theriault RL, Pololoff DA. Acute thyroid dysfunction (thyroiditis) after therapy with interleukin-2. Horm Metab Res 1992;24:434-8.
14. Mattijssen VJM, De Mulder PHM, Van Liessum PA, Corstens FHM, Franks CR, Wagener DJT. Hypothyroidism and goiter in a patient during treatment with interleukin-2. Cancer 1990;65:2686-8.
15. Hartmann LC, Urba WJ, Steis RG, et al. Hypothyroidism after interleukin-2 therapy [Letter]. J Clin Oncol 1989;7:686-7.
16. Atkins M, Mier J, Demchak P, Robert N, Parkinson D, Kaplan M. Thyroid dysfunction following IL-2 therapy [Abstract]. Proc ASCO 1990;9:186.
17. Yang JC, Topalian SL, Parkinson D, et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 1994;12:1572-6.
18. Besana C, Sabbadini MG, Corti C, et al. Autoimmune thyroiditis following interleukin-2 and LAK cell therapy for metastatic renal cell carcinoma: correlation with tumor regression. Tumori 1991;77:339-41.
19. Shulman KL, Thompson JA, Benyunes MC, Winter TC, Fefer A. Adverse reactions to intravenous contrast media in patients treated with interleukin-2. J Immunother 1993;13:208-12.
20. Heywood GR, Rosenberg SA, Weber JS. Hypersensitivity reactions to chemotherapy agents in patients receiving chemoimmunotherapy with high-dose interleukin-2. J Natl Cancer Inst 1995;87:915-22.
21. Kragel AH, Travis WD, Feinberg L, et al. Pathologic findings associated with interleukin-2-based immunotherapy for cancer: a postmortem study of 19 patients. Hum Pathol 1990;21:493-502.
22. Burman P, Tötterman TH, Öberg K, Karlsson FA. Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J Clin Endocrinol Metab 1986;63:1086-90.
23. Fentiman IS, Balkwill FR, Thomas BS, Russell MJ, Todd I, Bottazzo GF. Eur J Cancer Clin Oncol 1988;24:1299-303.